Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $33.3 million.

  • Innate Pharma's Total Current Liabilities fell 1908.0% to $33.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $33.3 million, marking a year-over-year decrease of 1908.0%. This contributed to the annual value of $35.2 million for FY2024, which is 1735.58% down from last year.
  • As of Q2 2025, Innate Pharma's Total Current Liabilities stood at $33.3 million, which was down 1908.0% from $35.2 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Total Current Liabilities peaked at $91.4 million during Q4 2021, and registered a low of $33.3 million during Q2 2025.
  • Moreover, its 5-year median value for Total Current Liabilities was $42.2 million (2022), whereas its average is $50.8 million.
  • The largest annual percentage gain for Innate Pharma's Total Current Liabilities in the last 5 years was 6850.28% (2021), contrasted with its biggest fall of 9993.77% (2021).
  • Innate Pharma's Total Current Liabilities (Quarter) stood at $91.4 million in 2021, then tumbled by 53.85% to $42.2 million in 2022, then grew by 1.12% to $42.6 million in 2023, then decreased by 17.36% to $35.2 million in 2024, then fell by 5.49% to $33.3 million in 2025.
  • Its Total Current Liabilities was $33.3 million in Q2 2025, compared to $35.2 million in Q4 2024 and $41.2 million in Q2 2024.